Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Amortizatization of Intangibles: 2022-2024

Historic Amortizatization of Intangibles for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $10.0 million.

  • Entrada Therapeutics' Amortizatization of Intangibles fell 77.00% to $739,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 41.69%. This contributed to the annual value of $10.0 million for FY2024, which is 73.35% up from last year.
  • Entrada Therapeutics' Amortizatization of Intangibles amounted to $10.0 million in FY2024, which was up 73.35% from $5.8 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Amortizatization of Intangibles registered a high of $10.0 million during FY2024, and its lowest value of -$151,000 during FY2022.
  • In the last 3 years, Entrada Therapeutics' Amortizatization of Intangibles had a median value of $5.8 million in 2023 and averaged $5.2 million.
  • Data for Entrada Therapeutics' Amortizatization of Intangibles shows a peak YoY skyrocketed of 3,927.15% (in 2023) over the last 5 years.
  • Entrada Therapeutics' Amortizatization of Intangibles (Yearly) stood at -$151,000 in 2022, then skyrocketed by 3,927.15% to $5.8 million in 2023, then spiked by 73.35% to $10.0 million in 2024.